Independent Advisor Alliance increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,337 shares of the company’s stock after purchasing an additional 1,327 shares during the period. Johnson & Johnson makes up 1.1% of Independent Advisor Alliance’s portfolio, making the stock its 17th biggest position. Independent Advisor Alliance’s holdings in Johnson & Johnson were worth $25,380,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of the business. Atlantic Private Wealth LLC bought a new stake in Johnson & Johnson in the 1st quarter valued at approximately $32,000. 25 LLC bought a new stake in Johnson & Johnson in the 1st quarter valued at approximately $55,000. Horizons Wealth Management lifted its stake in Johnson & Johnson by 1,730.0% in the 2nd quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after acquiring an additional 346 shares in the last quarter. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $66,000. Finally, Sanctuary Wealth Management L.L.C. bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $109,000. Institutional investors own 68.40% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on JNJ. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Wells Fargo & Company decreased their target price on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a report on Thursday, August 31st. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 18th. Finally, Atlantic Securities boosted their target price on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $169.19.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $153.00 on Monday. The stock’s 50-day simple moving average is $161.23 and its 200 day simple moving average is $162.45. The firm has a market capitalization of $397.64 billion, a PE ratio of 11.36, a price-to-earnings-growth ratio of 3.09 and a beta of 0.55. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.71% and a net margin of 36.32%. The business had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. During the same period last year, the firm posted $2.59 earnings per share. Johnson & Johnson’s revenue was up 6.3% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post 10.1 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st will be paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.11%. The ex-dividend date is Monday, November 20th. Johnson & Johnson’s payout ratio is 35.34%.
Insider Activity
In related news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Profitably Trade Stocks at 52-Week Highs
- Bargain Alert: Crocs a Footwear Brand With Single Digit P/E Ratio
- How to Invest in E-Commerce: A Guide
- MarketBeat Week in Review – 10/16 – 10/20
- Best Restaurant Stocks to Invest in Now
- Institutions Buy Consumer Staples, is the Bottom in?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
